September 22nd 2023
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor-positive, HER2-negative breast cancer were treated with datopotamab deruxtecan.
September 19th 2023
Trastuzumab Deruxtecan Maintains Durable QOL in HER2+ Breast Cancer
July 17th 2023Health-related quality of life measures from the phase 3 DESTINY-Breast03 trial showed that patient-reported outcomes and time of hospitalization data favored trastuzumab deruxtecan despite having a longer duration of treatment than trastuzumab emtansine.
Read More
Medical Meeting Places Spotlight on the Management of Breast Cancer
May 4th 2023In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed the key breast cancer topics during the Miami Cancer Institute Women’s Cancer Symposium and her presentation regarding HER2-positive breast cancer .
Read More
EARLY-MYO-BC Trial Examines Cardiac Impacts of Pyrotinib in HER2+ Breast Cancer
April 13th 2023Results from the EARLY-MYO-BC trial assessing the pyrotinib’s cardiac impacts may help researchers select an appropriate anti-HER2 treatment when managing patients with HER2-positive breast cancer.
Read More
FDA Accepts BLA of HLX02 for Patients With HER2-Expressing Cancers
April 5th 2023Multiple trials and techniques have evaluated treatment with HLX02 compared with trastuzumab. Now, the FDA has accepted the biologics license application HLX02 for patients with HER2-overexpressing metastatic breast cancer, breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma.
Read More
BDC-1001 With/Without Nivolumab Elicits Clinical Responses Across Solid Tumors
April 4th 2023Data from a phase 1/2 study of BDC-1001 alone or with nivolumab supports selection of a recommended phase 2 dose, advancement of further phase 2 studies, and assessment of the agent in combination with pertuzumab.
Read More
ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+/HER2- Breast Cancer
March 15th 2023Promising findings from the phase 2 ELAINE-1 and ELAINE-2 trials have led to the start of a phase 3 study where investigators will evaluate lasofoxifene and abemaciclib as a treatment for patients with ER-positive/HER2-negative breast cancer and an ESR1 mutation.
Read More
Emerging Data Behind 2 Antibody Drug Conjugates for Breast and Prostate Cancer
February 24th 2023Experts addressed ARX788 for patients with HER2-positive breast cancer, and a data update from the update for APEX-01 evaluating ARX517 in patients with prostate cancer was provided during a virtual analyst and investor day.
Read More
Anti-HER2 Therapy and Weekly Paclitaxel Show AMH Decline in HER2+ Breast Cancer
February 13th 2023In the biomarker analysis of the phase 3 NeoALTTO study, a small reduction in antimüllerian hormone levels were seen during 2 weeks of anti-HER2 treatment alone followed by a significant decline in most patients with HER2-positive breast cancer after combining with weekly paclitaxel.
Read More
Trastuzumab Deruxtecan Shows Promising Efficacy for Certain Patients With Breast Cancer
February 6th 2023Findings from the DEBBRAH trial showed that the use of trastuzumab deruxtecan in patients with HER2-positive advanced breast cancer showed promising efficacy for those with brain metastases.
Read More
Trastuzumab Deruxtecan Maintains Survival Advantage Over T-DM1 After Years HER2+ mBC
December 7th 2022Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in overall versus TDM-1 as well as a continued PFS benefit, according to Sara A. Hurvitz, MD.
Read More
Early Clinical Activity Observed With TAC01-HER2 in HER2-Positive Solid Tumors
October 20th 2022TAC01-HER2 elicited encouraging safety and clinical activity in patients with HER2-positive solid tumors with no dose limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity observed.
Read More
Recommended Approaches to Treatment for Early-Stage HER2+ Breast Cancer
October 13th 2022During a Targeted Oncology case-based roundtable event, Jennifer M. Matro, MD, discussed the data supporting systemic therapies for treatment of early-stage HER2-positive breast cancer including trastuzumab and pertuzumab.
Read More
Atezolizumab Added to SOC in HER2-Positive Breast Cancer Does Not Increase Responses
September 24th 2022Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.
Read More
Combination of Abemaciclib and Trastuzumab Improves OS in HR+, HER2+ Advanced Breast Cancer
September 10th 2022Adding abemaciclib to trastuzumab improved overall survival in women with with hormone receptor–positive, HER2-positive advanced breast cancer, according to new findings discussed at the 2022 ESMO Congress.
Read More